Vitrolife (VITR.ST) Stock Analysis & AI Equity Report
Vitrolife (VITR.ST) overview
Vitrolife (VITR.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Vitrolife reported revenue of SEK 3,440m and operating profit of SEK 616m; the year-end share price was 137.00 SEK and market capitalisation was SEK 18,553m. Vitrolife is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Vitrolife's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Vitrolife
Vitrolife AB develops and supplies products, technologies and genetic testing services for assisted reproduction, mainly to IVF clinics and laboratories. Its portfolio covers consumables used through the IVF process, time-lapse and laser systems, witnessing solutions, and reproductive genetics services and kits. The company also provides training, support and related services worldwide.
Generate the Vitrolife report
Vitrolife is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Vitrolife and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.